January 28, 2015 1:32 PM ET


Company Overview of Sandoz International GmbH

Company Overview

Sandoz International GmbH engages in developing, manufacturing, and marketing generic pharmaceutical products. The company offers oral solids, gels, patch technologies, inhalers, anti-infective medicines, antibiotics, cardiovascular medicines, treatments for central nervous system disorders, gastrointestinal medicines, and oncology and respiratory therapies; medications for blood and blood forming organ disorders; and injectables, including liquid vials, lyophilized vials, powder for oral suspensions, and pre-filled syringes. It also offers biopharmaceuticals, such as biosimilars; oncology injectables; pharmaceutical intermediates, active pharmaceutical ingredients, and finished dosage forms...

Industriestrasse 25

Holzkirchen,  83607



49 8024 476 0


49 8024 476 2599

Key Executives for Sandoz International GmbH

Chairman of the Executive Board and Head of Anti-Infectives
Global Head
Age: 40
Chief Financial Officer
Head of North American Operations and President of Sandoz US
Head of Legal and General Counsel
Compensation as of Fiscal Year 2014.

Sandoz International GmbH Key Developments

Sandoz Announces US Market Introduction of Tobramycin Inhalation Solution, USP, Generic Version of TOBI

Sandoz announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation 1. Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa. Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 worldwide) have cystic fibrosis2. Sandoz is marketing tobramycin inhalation solution, USP in 300 mg/5 mL single-dose ampules, the same size and strength that is currently marketed by the brand.

Sandoz Launches Authorized Generic Version of Diovan in US

Sandoz announced the US introduction of an authorized generic version of Diovan (valsartan) tablets for the treatment of high blood pressure (HBP). This launch follows the Sandoz US introduction of an authorized generic version of Diovan HCT (valsartan and hydrochlorothiazide) in 2012. Both Diovan and Diovan HCT are marketed in the US by Novartis Pharmaceuticals Corporation (NPC) and are indicated for the treatment of HBP. The most common side effects seen with valsartan in people with high blood pressure are headache, dizziness, flu symptoms, tiredness, and stomach (abdominal) pain. The most common side effects of valsartan seen in people with heart failure are dizziness, low blood pressure, diarrhea, joint and back pain, tiredness, and high blood potassium.

Sandoz Launches Three New Products in Japan, Including Authorized Generics of Valsartan and Zoledronic Acid

Sandoz announced the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan® Tablets, zoledronic acid, a generic version of Novartis’ Zometa® for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent® Tablets LD. Valsartan and Losarhyd are indicated for the treatment of hypertension. Zoledronic Acid is indicated for the treatment of hypercalcemia of malignancy.

Similar Private Companies By Industry

Company Name Region
BMP Labor für medizinische Materialprüfung GmbH Europe
Chiesi GmbH Europe
Spinal Cord Therapeutics GmbH Europe
MSD Sharp & Dohme GmbH Europe
FOCUS Clinical Drug Development GmbH Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sandoz International GmbH, please visit www.sandoz.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.